Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target stud...

Por Kumar, S., Jang, H. C., Demirağ, N. G., Skjøth, T. V., Endahl, L., Bode, B.
Publicado no Diabet Med (2016)

Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co‐formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomiz...

Por Rodbard, H. W., Cariou, B., Pieber, T. R., Endahl, L. A., Zacho, J., Cooper, J. G.
Publicado no Diabetes Obes Metab (2016)

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

Por Ratner, R E, Gough, S C L, Mathieu, C, Del Prato, S, Bode, B, Mersebach, H, Endahl, L, Zinman, B
Publicado em 2013